Genetically modified, covered with a membrane viral vector

 

The invention relates to genetic engineering of viruses. Proposed viral vector, covered with a membrane that encodes a transmembrane protein that contains deletions of one or more amino acids. The viral vector capable of infecting cells of insects and replicate in them, but is unable to replicate in mammalian cells. The viral vector suitable for the production of viral vaccines. 8 C.p. f-crystals, 5 Il., table 2.

Description text in facsimile form (see graphic part).

Claims

1. Genetically modified, covered with a membrane viral vector that encodes a transmembrane envelope protein, which is able to penetrate or to properly integrate into the cell membrane in insect cells, but not in mammalian cells due to the deletion of one or more amino acids in the specified transmembrane protein, despite the fact that the viral vector capable of infecting cells of insects and produce progeny virus in insect cells, capable of infecting mammalian cells, but not to produce progeny virus in mammalian cells.

2. Genetically modified, covered with a membrane VIRUSNAME and is virus vector arthropods.

3. Genetically modified, covered with a membrane viral vector under item 1, characterized in that the viral vector is derived from a virus selected from the group consisting of togaviruses, flaviviruses, bunyaviruses, enveloped viruses that can replicate in vivo in mammals and insects, and enveloped viruses that replicate in mammalian cells and insect as a result of genetic modification or virus, or cells.

4. Genetically modified, covered with a membrane viral vector under item 1, characterized in that the said insect cells are cells of the mosquito.

5. Genetically modified, covered with a membrane viral vector for p. 4, characterized in that the cells of the mosquito is Aedes albopictus cells.

6. Genetically modified, covered with a membrane viral vector under item 1, characterized in that the viral vector is a virus Sindbis specified transmembrane protein is a viral glycoprotein E2 and specified the mammal is a human.

7. Genetically modified, covered with a membrane viral vector under item 1, characterized in that said viral vector of the, the specified transmembrane protein selected from the group consisting of glycoprotein E1 glycoprotein E2 and G-protein, despite the fact that the viral vector is selected from the group consisting of simple herpes virus, HIV, rabies virus, hepatitis virus, and respiratory syncytial virus.

9. Genetically modified, covered with a membrane viral vector under item 1, characterized in that said transmembrane protein is a protein Env, as specified viral vector is a tumor RNA virus.

 

Same patents:

The invention relates to medicine and relates to chimeric live attenuated infectious virus, which is used to create chimeric vaccines flavivirus

The invention relates to the field of biotechnology and genetic engineering and can be used in the diagnosis of diseases of pigs

The invention relates to the field of Virology and can be used in the production of vaccines

The invention relates to genetic engineering and can be used in veterinary Virology for detecting diseases of farm animals, namely: Aujeszky's disease

The invention relates to biotechnology, in particular genetic engineering, is a recombinant strain of vaccinia virus, causing the synthesis of structural proteins of the virus Venezuelan encephalomyelitis of horses (VAL) in infected cells and protective immunity against VAL have them vaccinated laboratory animals, as well as the method of construction of this strain

The invention relates to a method of producing tridecapeptide formula I: H-His-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly-OH and aims to simplify the process and increase the yield of the target product, as well as Pentapeptide formula II: X-His(X)-Gly-Val-Ser(Y)-Gly-OH, which is an intermediate compound in the synthesis

The invention relates to the field of chromatography of proteins, can be used in biotechnology for purification and fractionation of enzymes

The invention relates to a method of removing etiological (causal) factor (factors) vector-borne (transmitted) spongiform encephalopathies (TSE) of protein solutions, in particular from blood products, which will be used for therapeutic and other medical purposes

The invention relates to an improved method for producing adducted end of the condensation products, which are Schiff bases, components of which include a protein having useful activity in animals, and aromatic o-hydroxyaldehyde, which connect the above components in an aqueous medium at pH 7.0 or higher to form a reaction mixture under conditions effective to conduct specified the condensation reaction essentially to completion by using the stage of fast compared to drying in ambient conditions removal 97,0 to 99.9% by weight, preferably approximately 98,0 - 99,0% by weight of water, already present or formed during this reaction, condensation, consistent with maintaining the integrity of reagents condensation and adductor final product

The invention relates to enzymatic tsepliaeva the linker associated with the solid phase selected from the group comprising ceramics, glass, latex, cross stitched polystyrenes, cross stitched polyacrylamides or other resins, natural polymers, silica aerogels and hydrogels, which functional group synthesize organic compounds, and the linker contains place a recognizable hydrolytic enzyme, and the reaction with the enzyme disintegrates so that the synthesized product does not leave any sections of the linker molecules, and this place, recognizable by an enzyme selected from the group comprising ester bonds, aminokislotnye communication ether linkages, ester bonds in esters of phosphoric acid and glycosidic bonds, and which is recognizable by the enzyme and a place at which the released product synthesis through the collapse of the linker are different, and the method of its production

The invention relates to compounds of the formula X1-Leu-His-Lys(R1)-Leu-Gln-Thr-Tyr(R2)-Pro-Y, where X1- H-, A1O-CO-, H-Lys(R3)-Leu-Ser-Gln-Glu(B4)-, A1O-CO-Lys(R3)-Leu-Ser-Gln-Glu(B4)-; Y is-OH, -Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2;1there is tert-butyl; R1- protective group of the formula IN the1O-CO - Epsilon-amino group of the Lys residue, R2- protective group of the formula IN the2About-WITH - hydroxyl group of residue Taut, R3- protective group of the formula IN the3O-CO - Epsilon-amino group of the Lys residue IN4- protective group for the gamma-carboxyl group of Glu residue, and1IN2IN3and4may be the same or different and are selected from the range: 2-alkylsulfonates, 2-phenylsulfonyl, 2-(substituted aryl)sulfonylated

The invention relates to an improved process for the preparation of collagen from solubilizing and purified, may pasensyahan extract non-sterile native or telopeptide collagen, including: i) the stage of mixing and shearing of the extract in mixer with dual lateral incisors with the gradual increase of the initial rate of mixing at 500-1000 rpm without exceeding the speed of 10000 rpm and the gradual increase of temperature for 2-10oWith, preferably 3-5oWith, thus, to increase the initial ambient temperature of the extract to the maximum controlled temperature, component not exceeding 50oWith, and then (ii) the stage of sterilization in the liquid environment of the extract with obtaining sterile collagen in native or telopeptides, native or telopeptide collagen type I, obtained with the above method, with the following characteristics or properties: ratio2(I)1/1(I)2from 0.48 to 0.52; sterility in accordance with the standard of the European Pharmacopoeia; total nitrogen from 17,0 to 18.7%; hydrox

The invention relates to the field of biotechnology and biochemistry, and can be used in medicine

The invention relates to a method for cyclosporine And high purity by purification of the crude product containing cyclosporiasis complex by multi-step chromatography on silica gel at high load columns from 10 to 52%, using as eluent a mixture of toluene with acetone in an amount of from 10 to 30 vol.% or toluene with ethyl acetate in an amount of from 10 to 35 vol.%, cyclosporine And high purity with content cyclosporine L, U and D less than 0.05% and the content of cyclosporine and < 0,02% vol., industrial method of purification of cyclosporin a from a crude product containing complex cyclosporiasis

FIELD: biotechnology, biochemistry.

SUBSTANCE: invention relates to extracts prepared from vegetable somatic embryos for the cell-free translation system and/or the coupled transcription-translation system. Method involves preparing embryonic callus from the primary material and the embryonic suspension culture. After induction of the secondary somatic embryogenesis extract is prepared from somatic embryos. Based on the extract the diagnostic system is developed for detection of biologically active compounds. Invention provides overcoming the species limitations and strain specificity and to attain the high effectiveness of the cell-free translation system and the coupled transcription-translation system also.

EFFECT: improved preparing method, valuable biological and biochemical properties of system.

49 cl, 5 dwg, 2 tbl, 9 ex

FIELD: bioengineering; genetic engineering; medicine; methods of production casamino acids.

SUBSTANCE: the invention is pertaining to the field of bioengineering, genetic engineering, medicine, in particular, to the methods of production of components for nutrient mediums from hydrolysates of animal protein. The invention offers the method of production of casamino acids by the method of the gel permeation chromatography of the hydrolyzed crude acid casein with the contents of the general nitrogen - 0.7-0.95 g in 100 ml of the solution and concentration - 6-10 % on Sefadex G-15, eluating by a distilled water of fractions of an eluate, selection of the active fractions of an eluate by a spectophotometery of portions of the eluate (D254), evaporation of the active fractions under vacuum at the temperature of no more than 55°C. The method allows to simplify the process of production of casamino acids, to reduce its cost and also to obtain casamino acids possessing the high growth- stimulating activity.

EFFECT: the invention ensures simplification of the process of production of casamino acids, reduction of its cost and also production of casamino acids possessing the high growth- stimulating activity.

2 cl, 2 dwg, 1 tbl, 1 ex

Up!